X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to advance the development of PredicineCARE, a blood cfDNA NGS assay, to identify NSCLC patients who may benefit from targeted therapy, APL-101 (vebreltinib), a novel, potent, selective and orally bioavailable small molecule c-Met inhibitor.
Lead Product(s): Vebreltinib
Therapeutic Area: Oncology Product Name: APL-101
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Predicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 05, 2024
Details:
APL-106 (uproleselan) is an investigational, first-in-class E-selectin antagonist, which is under phase 3 clinical development for the treatment of of adults with relapsed or refractory acute myeloid leukemia (relapsed/refractory AML).
Lead Product(s): Uproleselan,Mitoxantrone,Etoposide
Therapeutic Area: Oncology Product Name: APL-106
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
APL-101 (vebreltinib) is a small-molecule inhibitor that targets MET tyrosine kinase activity. It is being developed for the treatment of MET Exon 14 skip non-small cell lung cancer.
Lead Product(s): Vebreltinib
Therapeutic Area: Oncology Product Name: APL-101
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
APL-101 (vebreltinib) is a highly specific cMet inhibitor which is under phase 2 clinical development in non-small cell lung cancer and other solid tumors with MET dysregulations.
Lead Product(s): Vebreltinib
Therapeutic Area: Oncology Product Name: APL-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
Apollomics will use the financing to advance APL-101 (vebreltinib), a highly specific cMet inhibitor, in non-small cell lung cancer and other solid tumors with cMet dysregulation.
Lead Product(s): Vebreltinib
Therapeutic Area: Oncology Product Name: APL-101
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Maxpro Capital Acquisition Corp.
Deal Size: $23.6 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 30, 2023
Details:
The primary endpoint of APL-106 is overall survival and Secondary outcome measures the rate and duration of remission, and whether APL-106 can reduce the rate of oral mucositis, a chemotherapy-related side effect.
Lead Product(s): Uproleselan,Mitoxantrone,Etoposide
Therapeutic Area: Oncology Product Name: APL-106
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2021
Details:
APL-106 (uproleselan injection) is an innovative drug discovered and developed by GlycoMimetics. Apollomics licensed uproleselan from GlycoMimetics, and Apollomics has the rights to clinical development, production and commercial sales in the Greater China market.
Lead Product(s): Uproleselan
Therapeutic Area: Oncology Product Name: APL-106
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2021
Details:
APL-102 has also shown favorable preclinical pharmacokinetic (PK) and safety profiles with no serious off-target activity observed. APL-102 has the potential to be used as a single agent or in combination with other oncology agents.
Lead Product(s): APL-102
Therapeutic Area: Oncology Product Name: APL-102
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2021
Details:
The Phase 1 clinical trial in China is a part of the Phase 1 and Phase 3 bridging clinical study of APL-106 in combination with chemotherapy in adults with relapsed or refractory AML.
Lead Product(s): Uproleselan
Therapeutic Area: Oncology Product Name: APL-106
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: GlycoMimetics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
Agreement will expand clinical development for a potent and selective small molecule,Tegavivint, targeting TBL1, a downstream target in the Wnt/b-catenin signaling pathway.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Product Name: BC2059
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Iterion Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
